Advances in the pharmacotherapy of hereditary angioedema

Laura M. Cotiguala, Kelli L. Coover, Againdra K. Bewtra, Mark A. Malesker

Research output: Contribution to specialist publicationArticle

Abstract

Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

Original languageEnglish
PagesHS17-HS21
Volume40
No10
Specialist publicationU.S. Pharmacist
StatePublished - Oct 16 2015

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this